| Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy B Surial, F Chammartin, J Damas, A Calmy, D Haerry, M Stöckle, ... Clinical Infectious Diseases 77 (5), 729-737, 2023 | 36 | 2023 |
| Cardiovascular risk assessment in people living with HIV compared to the general population B Delabays, M Cavassini, J Damas, H Beuret, A Calmy, B Hasse, ... European Journal of Preventive Cardiology 29 (4), 689-699, 2022 | 26 | 2022 |
| Prevalence of HIV, syphilis, and assessment of the social and structural determinants of sexual risk behaviour and health service utilisation among MSM and transgender women in … M Storm, K Deuba, J Damas, U Shrestha, B Rawal, R Bhattarai, ... BMC infectious diseases 20, 1-14, 2020 | 24 | 2020 |
| Impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital A Munting, J Regina, J Damas, L Lhopitallier, A Kritikos, B Guery, L Senn, ... Clinical Microbiology and Infection 28 (4), 558-563, 2022 | 15 | 2022 |
| Venezuela's health-care crisis RJ Bello, JJ Damas, FJ Marco, JS Castro Lancet 390 (10094), 551, 2017 | 12 | 2017 |
| Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV J Damas, B Ledergerber, I Nadin, PE Tarr, M Stoeckle, U Kunze, ... Aids 35 (15), 2469-2480, 2021 | 9* | 2021 |
| Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV J Damas, A Munting, J Fellay, D Haerry, C Marzolini, PE Tarr, A Steffen, ... Clinical Infectious Diseases 79 (4), 990-998, 2024 | 6 | 2024 |
| Cerebrospinal fluid HIV-1 escape in patients with neurocognitive symptoms: pooled data from a neuro-HIV platform and the NAMACO study P Filippidis, J Damas, B Viala, F Assal, ON Tshikung, P Tarr, T Derfuss, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 93 (3), 219-228, 2023 | 5 | 2023 |
| Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after … A Munting, J Damas, B Viala, G Prod’hom, B Guery, L Senn Antimicrobial Resistance & Infection Control 11 (1), 165, 2022 | 5 | 2022 |
| Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virus B Jakeman, AU Scherrer, KEA Darling, J Damas, M Bieler-Aeschlimann, ... Open Forum Infectious Diseases 9 (9), ofac457, 2022 | 5 | 2022 |
| One for all, all for one: neuro‐HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV J Damas, KEA Darling, P Bidlingmeyer, I Nadin‐Debluë, M Bieler, ... HIV medicine 24 (6), 738-748, 2023 | 4 | 2023 |
| Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study F Blondet, V Kraege, M Cavassini, JD Fernandez, P Vollenweider, ... AIDS 37 (6), 935-939, 2023 | 3 | 2023 |
| Prevalence of HIV, Hepatitis C and its related risk behaviours among women who inject drugs in the Kathmandu Valley, Nepal: A cross-sectional study J Damas, M Storm, LR Pandey, G Marrone, K Deuba Therapeutic Advances in Infectious Disease 8, 20499361211062107, 2021 | 3 | 2021 |
| HIV pre-exposure prophylaxis: physicians are not prepared M Badoux, J Damas, C Manuel, M Cavassini, A Munting Revue Medicale Suisse 20 (869), 748-755, 2024 | | 2024 |
| Prolonged outpatient parenteral antimicrobial treatment: frequency and evolution over a six-year period in a Swiss University Hospital A Munting, J Damas, L Arensdorff, M Cavassini, S de Vallière BMC Infectious Diseases 24, 1, 2024 | | 2024 |
| External validation of the Dat'AIDS score: A risk score for predicting 5‐year overall mortality in people living with HIV aged 60 years or older M Hentzien, J Frossard, R Kouyos, V Prendki, J Damas, E Hofmann, ... HIV medicine 25 (1), 72-82, 2024 | | 2024 |
| Multidisciplinary assessment and management of neurocognitive complaints in people living with HIV J Damas, A Berney, M Bieler-Aeschlimann, M Cavassini, R Du Pasquier Revue Medicale Suisse 19 (824), 797-799, 2023 | | 2023 |
| HIV-related stigma and its relationship to quality of life among people living with HIV enrolled in the Swiss HIV Cohort Study J Damas, A Justice, D Satre, M Silverberg, J Sterne, A Wrona, K McGinnis, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 169-170, 2022 | | 2022 |
| External validation of the Dat'AIDS score for predicting 5-year mortality among elderly people with HIV in the Swiss HIV Cohort Study M Hentzien, J Frossard, R Kouyos, V Prendki, J Damas, E Hofmann, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 9-10, 2022 | | 2022 |
| Prevalence of HIV-related stigma among people with HIV in Switzerland: addressing the elephant in the room E Kampouri, J Damas, K Kusejko, B Ledergerber, D Braun, ON Tshikung, ... AIDS, 10.1097, 2022 | | 2022 |
Matthias CavassiniHead of the Infectious Diseases outpatient clinic, CHUV, Lausanne, Switzerland在 chuv.ch 的电子邮件经过验证
